Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
Investing.com - Barclays has assumed coverage on Cytokinetics (NASDAQ:CYTK) with an Overweight rating and a price target of $87.00, representing 36% upside from the current price of $64.01. The stock ...
Near-infrared spectroscopy (NIRS)-monitored cerebral oxygenation using the regional cerebral saturation (rScO 2) and the cerebral fractional tissue oxygen extraction (cFTOE), derived from rScO 2 and ...
Bristol Myers Squibb’s (BMS) Phase III trial investigating Camzyos (mavacamten) in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) has failed to meet its dual primary endpoints. In ...
Aortic stenosis is 1 of the most common heart valve diseases among adults. When symptoms develop, prognosis is poor, and current guidelines recommend prompt aortic valve replacement. Depending of the ...
The last 3 decades have seen a revolution in our understanding of the physiology and pathophysiology of iron metabolism in the cardiovascular system. In this review, we highlight the key role of iron ...
Abstract: Objective: Current intrapartum fetal monitoring technology is unable to provide physicians with an objective metric of fetal well-being, leading to degraded patient outcomes and increased ...
7 Royal Surrey County Hospital NHS Foundation Trust and Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results